DURECT Corporation (DRRX) Stock Analysis

DURECT Corporation (DRRX) Healthcare & Pipeline Overview

DURECT Corporation, established in 1998, is a biopharmaceutical company specializing in epigenetic regulator and pharmaceutical programs. Their product offerings include ALZET osmotic pumps for research, larsucosterol (DUR-928) in clinical trials for liver diseases, POSIMIR for post-surgical pain, and Methydur for ADHD, positioning them in the specialty drug market.

What Is the Investment Thesis for DRRX?

DURECT Corporation presents a speculative investment opportunity within the biopharmaceutical sector. The company's primary value driver is the potential success of larsucosterol (DUR-928) in treating alcohol-associated hepatitis (AH) and nonalcoholic steatohepatitis (NASH). Positive Phase IIb clinical trial results for AH could serve as a significant catalyst, potentially leading to partnerships or acquisition. The company's established ALZET osmotic pump business provides a steady revenue stream, supporting ongoing research and development. However, the company's small market capitalization of $59.3M and limited resources introduce significant risks, including potential clinical trial failures, regulatory hurdles, and the need for additional capital. The company's high profit margin of 66.1% and gross margin of 92.0% suggest efficient operations, but these metrics may fluctuate based on R&D expenses and product sales.

Based on FMP financials and quantitative analysis

DRRX Key Highlights

Market capitalization of $59.3M, reflecting its small size and potential for high growth or volatility.

• P/E ratio of 73.5, indicating investors are paying a premium for its earnings, possibly due to future growth expectations.
• Profit margin of 66.1%, significantly higher than the industry average, suggesting efficient cost management or high-value products.
• Gross margin of 92.0%, demonstrating strong pricing power and low cost of goods sold, primarily driven by its ALZET product line.
• Beta of 0.93, indicating that the stock is slightly less volatile than the overall market.

Who Are DRRX's Competitors?

DRRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DRRX's Key Strengths?

Proprietary drug delivery technology.

• Established ALZET product line.
• Promising clinical pipeline with larsucosterol (DUR-928).
• High gross and profit margins.

What Are DRRX's Weaknesses?

Limited financial resources.

• Dependence on clinical trial outcomes.
• Small market capitalization.
• Limited commercial infrastructure.

What Could Drive DRRX Stock Higher?

DRRX catalyst: Phase IIb clinical trial results for larsucosterol (DUR-928) in alcohol-associated hepatitis (AH). Positive results could lead to partnerships or acquisition.

• Continued sales and marketing efforts for ALZET osmotic pumps.
• Potential for new strategic collaborations or licensing agreements.

What Are the Key Risks for DRRX?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Rich valuation — a P/E of 73.5 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Clinical trial failures for larsucosterol (DUR-928).
• Regulatory hurdles and delays in drug approval.
• Competition from larger pharmaceutical companies with greater resources.
• Need for additional capital to fund research and development.

What Are the Growth Opportunities for DRRX?

• Expansion of Larsucosterol (DUR-928) Indications: DURECT has the opportunity to expand the clinical development of larsucosterol (DUR-928) beyond alcohol-associated hepatitis (AH) and nonalcoholic steatohepatitis (NASH). Given its mechanism of action as an epigenetic regulator, DUR-928 could potentially be investigated for other inflammatory and metabolic diseases. The market for inflammatory diseases is substantial, with a global market size estimated at hundreds of billions of dollars. This expansion could significantly increase the potential market for DUR-928 and drive long-term growth.
• Strategic Partnerships and Licensing Agreements: DURECT can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborating with established players can provide access to funding, expertise, and distribution networks. Licensing agreements for POSIMIR or Methydur could generate upfront payments, milestone payments, and royalties, providing non-dilutive funding for the company's pipeline. The timeline for securing such agreements is dependent on clinical trial results and market interest.
• Commercialization of POSIMIR: DURECT has the opportunity to expand the commercialization of POSIMIR, its post-surgical pain product. While currently available, increased marketing efforts and strategic partnerships with hospitals and surgical centers could drive sales growth. The market for post-surgical pain management is substantial, with a global market size in the billions of dollars. Effective commercialization of POSIMIR could provide a steady revenue stream and contribute to the company's overall financial stability.
• Expansion of ALZET Pump Business: DURECT can further expand its ALZET osmotic pump business by developing new pump models, expanding its distribution network, and targeting new research applications. The ALZET pumps are widely used in preclinical research, and the demand for controlled drug delivery systems is expected to grow. Expanding the product line and market reach could drive incremental revenue growth for this established business.
• Development of Novel Epigenetic Regulators: DURECT can leverage its expertise in epigenetic regulation to develop novel drug candidates targeting other diseases. Epigenetic mechanisms play a role in a wide range of diseases, including cancer, neurological disorders, and autoimmune diseases. By identifying and developing new epigenetic regulators, DURECT can expand its pipeline and create new opportunities for growth. This is a longer-term growth strategy, with a timeline of several years for drug discovery and development.

What Are DRRX's Competitive Advantages?

• Proprietary drug delivery platforms and epigenetic regulator technologies.
• Established ALZET product line with a loyal customer base in research.
• Patent protection for key drug candidates and technologies.

What Does DRRX Do?

DURECT Corporation, founded in 1998 and headquartered in Cupertino, California, is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative medicines. The company's initial focus was on developing and utilizing its proprietary drug delivery platforms to create pharmaceutical products with improved efficacy, safety, and patient compliance. Over the years, DURECT has evolved to focus on epigenetic regulator and pharmaceutical programs, expanding its pipeline and therapeutic areas of interest. DURECT's product portfolio includes the ALZET product line, comprising osmotic pumps and accessories widely used in preclinical research for controlled drug delivery in laboratory animals. The company is also developing larsucosterol (DUR-928), an orally bioavailable small molecule currently in Phase IIb clinical trials for alcohol-associated hepatitis (AH) and having completed Phase Ib trials for nonalcoholic steatohepatitis (NASH). Additionally, DURECT offers POSIMIR, a post-surgical pain product designed to deliver bupivacaine for up to three days in adults, and Methydur for the treatment of attention deficit hyperactivity disorder (ADHD). DURECT markets and sells its ALZET product line through a direct sales force in the United States and through a network of distributors internationally. The company has established strategic collaborations with organizations such as Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Santen Pharmaceutical Co., Ltd., to further its research and development efforts and expand its market reach.

What Products and Services Does DRRX Offer?

• Researches and develops medicines based on epigenetic regulator programs.
• Offers ALZET osmotic pumps and accessories for research in laboratory animals.
• Develops larsucosterol (DUR-928) for alcohol-associated hepatitis and nonalcoholic steatohepatitis.
• Markets POSIMIR, a post-surgical pain product delivering bupivacaine.
• Develops Methydur for the treatment of attention deficit hyperactivity disorder (ADHD).
• Sells ALZET lines through direct sales in the US and distributors internationally.

How Does DRRX Make Money?

• Develops and out-licenses drug delivery technologies and pharmaceutical products.
• Generates revenue from sales of ALZET osmotic pumps and related accessories.
• Seeks strategic collaborations and partnerships for development and commercialization of drug candidates.

What Industry Does DRRX Operate In?

DURECT Corporation operates within the specialty pharmaceutical industry, a segment characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for liver disease treatments, particularly NASH and AH, is experiencing significant growth due to increasing prevalence and limited treatment options. DURECT's larsucosterol (DUR-928) targets this growing market. The company competes with larger pharmaceutical companies and smaller biotech firms developing novel therapies for liver diseases. Success in this industry requires strong clinical data, strategic partnerships, and effective commercialization strategies.

Who Are DRRX's Key Customers?

• Researchers in academia and pharmaceutical companies who use ALZET pumps.
• Patients requiring post-surgical pain management who use POSIMIR.
• Patients with ADHD who may use Methydur.
• Pharmaceutical companies partnering with DURECT for drug development.

Company Profile

DURECT Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Cupertino, US. The company is led by CEO James E. Brown D.V.M.. DRRX has traded publicly since 2000.

DURECT Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Return on equity for DURECT Corporation stands at 13.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.5%, showing how much profit it generates from its asset base. DRRX trades at a trailing price-to-earnings ratio of 73.47, above the Healthcare sector average of ~23x. Its free cash flow yield is -18.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.98 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 1.4%, the inverse of the P/E and a quick read on earnings relative to price.

DRRX Valuation & Market Position

With a $59.3M market cap, DURECT Corporation sits in the micro-cap segment of the market.

Wall Street analysts project DURECT Corporation revenue of about $1.0M for fiscal 2026, with EPS near $-0.70.

DRRX Financials

DRRX Latest News

Common Questions About DRRX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources